Aspira Women’s Health (NASDAQ:AWH) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reissued a “neutral” rating and set a $3.30 price target on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.

Aspira Women’s Health Price Performance

Aspira Women’s Health stock opened at $0.99 on Tuesday. Aspira Women’s Health has a 1-year low of $0.90 and a 1-year high of $6.75. The stock has a market cap of $12.33 million, a PE ratio of -0.68 and a beta of 1.54. The stock’s fifty day moving average is $2.39 and its two-hundred day moving average is $3.42.

Aspira Women’s Health (NASDAQ:AWH) last posted its earnings results on Tuesday, May 21st. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The firm had revenue of $2.15 million during the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the prior year, the business earned ($10.94) EPS. On average, research analysts expect that Aspira Women’s Health will post -1.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. Quantum Private Wealth LLC raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 76.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,156 shares of the company’s stock after purchasing an additional 21,788 shares during the quarter. Quantum Private Wealth LLC owned about 0.49% of Aspira Women’s Health worth $205,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.